Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 29Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Cholangiocarcinoma 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Cystectomy 2tislelizumab 1relatlimab 1enzalutamide 1durvalumab 1Urinary Diversion 1Radiosurgery 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1Microscopy 1Immunonutrition Diet 1Immune Checkpoint Inhibitors 1Gemcitabine 1Cystoscopy 1Cisplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Diseases × Immune Checkpoint Inhibitors × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡